Halozyme Therapeutics Inc (HALO)
Debt-to-capital ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-term debt | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Total stockholders’ equity | US$ in thousands | 363,821 | 452,703 | 289,424 | 177,808 | 83,808 | 249,181 | 151,033 | 65,850 | 169,798 | 96,991 | 293,171 | 260,256 | 196,953 | 281,674 | 119,748 | 67,595 | 151,047 | 98,988 | 105,577 | 58,042 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
December 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $—K ÷ ($—K + $363,821K)
= 0.00
Halozyme Therapeutics Inc has consistently maintained a debt-to-capital ratio of 0.00 across all reported quarters from March 31, 2020, to December 31, 2024. A debt-to-capital ratio of 0.00 indicates that the company has no debt in its capital structure during the specified time period. This signifies that the company has either been operating without any debt obligations or has been utilizing alternative financing sources to fund its operations and investments. A low or zero debt-to-capital ratio can be viewed positively by investors and creditors as it implies lower financial risk and greater financial stability for the company.
Peer comparison
Dec 31, 2024